Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 14/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 14/20 | 1.00 |
| ▸ | PDE5A | O76074 | 8/20 | 1.00 |
| ▸ | PDE1A | P54750 | 8/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 8/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185627 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL20756030 | 0.91 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5607953 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7160159 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7495374 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7818726 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7682562 | 0.88 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7673788 | 0.88 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7491632 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7491635 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| EP-0785789-B1 | DIAZEPINO-INDOLES AS PHOSPHODIESTERASE IV INHIBITORS | PFIZER (FR) | 2002-09-11 | — | — | EP | claimed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | disclosed |
| EP-3984555-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2022-04-20 | — | — | EP | disclosed |
| EP-3785733-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2022-01-05 | — | — | EP | disclosed |
| US-20210154177-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-27 | — | — | US | disclosed |
| US-20210145803-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-20 | — | — | US | disclosed |
| US-10940140-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2021-03-09 | — | — | US | disclosed |
| EP-3785733-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-03-03 | — | — | EP | disclosed |
| EP-3498297-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2019-06-19 | — | — | EP | disclosed |
| US-20190134011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2019-05-09 | — | — | US | disclosed |
| US-6878821-B2 | Contacting with oxidizing agent and fluorinated alcohol | WARNER-LAMBERT LLC (US) | 2005-04-12 | — | — | US | disclosed |
| WO-2004067006-A1 | COMBINATION OF A PDE IV INHIBITOR AND A TNF-ALPHA ANTAGONIST | PHARMACIA CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20030176723-A1 | Modifying chemoselectivity during oxidation of nitrogen compounds | BERNADELLI PATRICK (FR) | 2003-09-18 | — | — | US | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| US-6365585-B1 | USED AS ANTI-INFLAMMATORIES, ANTI-ALLERGICS, BRONCHODILATORS OR ANTI-ASTHMATICS AND ARE DEVOID OF DIGESTIVE OR CARDIAC SIDE-EFFECTS | WARNER-LAMBERT COMPANY | 2002-04-02 | — | — | US | disclosed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176723-A1 | Modifying chemoselectivity during oxidation of nitrogen compounds | NOX3, NOX1, NOX5 | PDE4A 4297/4885PDE4B 4275/4885PDE4C 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.